Literature DB >> 7846071

Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation.

P A Sieving1, J E Richards, F Naarendorp, E L Bingham, K Scott, M Alpern.   

Abstract

A human rhodopsin mutation, Gly-90-->Asp (Gly90Asp), cosegregated with an unusual trait of congenital nightblindness in 22 at-risk members of a large autosomal dominant kindred. Although rhodopsin mutations typically are associated with retinal degeneration, Gly90Asp-affected subjects up to age 33 did not show clinical retinal changes. Absolute threshold for visual perception was elevated nearly 3 logarithmic units in 7 individuals tested (ages 11-64), indicating greatly compromised rod threshold signaling. However, in vivo rhodopsin density was normal. Although the 38-year-old proband could not perceive dim lights, his rod increment threshold function was normal on brighter backgrounds. The impaired rod vision for dim but not bright backgrounds is consistent with a mechanism of increased basal "dark-light" from thermal isomerization equivalent to an increase of > 10(4) over that of wild-type rhodopsin. The Gly90Asp mutation on the second transmembrane helix places an extra negative charge in the opsin pocket; this could contribute to partial deprotonation of the retinal Schiff base and thereby increase photoreceptor noise. In vitro evidence had suggested that transducin is activated by the Gly90Asp mutation in the absence of both the retinal chromophore and light, termed "constitutive activity." The apparent preservation of functioning rods despite extensive and lifelong night-blindness in this kindred is inconsistent with one current hypothesis that chronic rod activation from constitutively active mutant rhodopsin necessarily contributes significantly to photoreceptor demise in human retinal dystrophies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7846071      PMCID: PMC42724          DOI: 10.1073/pnas.92.3.880

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.

Authors:  K B Mullis; F A Faloona
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  The density and photosensitivity of human rhodopsin in the living retina.

Authors:  M Alpern; E N Pugh
Journal:  J Physiol       Date:  1974-03       Impact factor: 5.182

3.  Rhodopsin regeneration in man.

Authors:  H Ripps; R A Weale
Journal:  Nature       Date:  1969-05-24       Impact factor: 49.962

4.  The Florida retinal densitometer.

Authors:  C Hood; W A Rushton
Journal:  J Physiol       Date:  1971-08       Impact factor: 5.182

5.  Night blindness revisited: from man to molecules. Proctor lecture.

Authors:  H Ripps
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-11       Impact factor: 4.799

6.  Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa.

Authors:  S Kaushal; H G Khorana
Journal:  Biochemistry       Date:  1994-05-24       Impact factor: 3.162

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Counting every quantum.

Authors:  B Sakitt
Journal:  J Physiol       Date:  1972-05       Impact factor: 5.182

9.  Rhodopsin and visual threshold in retinitis pigmentosa.

Authors:  H Ripps; K P Brin; R A Weale
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-08       Impact factor: 4.799

10.  The blue arcs of the retina.

Authors:  M Alpern; D Dudley
Journal:  J Gen Physiol       Date:  1966-01       Impact factor: 4.086

View more
  47 in total

Review 1.  Structural features of heterotrimeric G-protein-coupled receptors and their modulatory proteins.

Authors:  H LeVine
Journal:  Mol Neurobiol       Date:  1999-04       Impact factor: 5.590

2.  Structural, energetic, and mechanical perturbations in rhodopsin mutant that causes congenital stationary night blindness.

Authors:  Shiho Kawamura; Alejandro T Colozo; Lin Ge; Daniel J Müller; Paul S-H Park
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

3.  Molecular mechanisms of disease for mutations at Gly-90 in rhodopsin.

Authors:  Darwin Toledo; Eva Ramon; Mònica Aguilà; Arnau Cordomí; Juan J Pérez; Hugo F Mendes; Michael E Cheetham; Pere Garriga
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

Review 4.  Light and inherited retinal degeneration.

Authors:  D M Paskowitz; M M LaVail; J L Duncan
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

5.  Light/dark translocation of alphatransducin in mouse photoreceptor cells expressing G90D mutant opsin.

Authors:  Zack A Nash; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

6.  Congenital stationary night blindness associated with mutations in GRM6 encoding glutamate receptor MGluR6.

Authors:  E O'Connor; L E Allen; K Bradshaw; J Boylan; A T Moore; D Trump
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

7.  11-cis- and all-trans-retinols can activate rod opsin: rational design of the visual cycle.

Authors:  Masahiro Kono; Patrice W Goletz; Rosalie K Crouch
Journal:  Biochemistry       Date:  2008-06-19       Impact factor: 3.162

8.  Congenital stationary night blindness and a "Schubert-Bornschein" type electrophysiology in a family with dominant inheritance.

Authors:  S A Kabanarou; G E Holder; F W Fitzke; A C Bird; A R Webster
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

Review 9.  Constitutively active rhodopsin and retinal disease.

Authors:  Paul Shin-Hyun Park
Journal:  Adv Pharmacol       Date:  2014

10.  Night blindness and the mechanism of constitutive signaling of mutant G90D rhodopsin.

Authors:  Alexander M Dizhoor; Michael L Woodruff; Elena V Olshevskaya; Marianne C Cilluffo; M Carter Cornwall; Paul A Sieving; Gordon L Fain
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.